CTRI/2024/04/066012尚未招募3 期
A RANDOMIZED, OPEN LABEL, PLACEBO CONTROLLED STUDYTO EVALUATE THE ROLE OF TAB NISHA-AMALAKI AND MAHADADIMADI GHRITA AS ADJUVANT THERAPY IN TYPE 1 DIABETES (SAHAJA PRAMEHA) IN CHILDREN - NI
All India Institute of Ayurveda, New Delhi0 个研究点目标入组 0 人开始时间: 待定最近更新:
试验速览
- 阶段
- 3 期
- 状态
- 尚未招募
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1.Age between 02 -16 years.
- •2.Pre-diagnosed cases of T1DM (Type 1 diabetes)
- •3.Patients having FBS =126mg/dl, PPBS =200 mg/dl, HbA1c = 6.5%
- •4.Requirement of insulin as the initial mode of treatment at the time of diagnosis of diabetes.
- •5.Brittle diabetes (mellitus)
- •6.Diabetes (mellitus) due to autoimmune process
- •7.Diabetes (mellitus) due to immune mediated pancreatic islet beta-cell destruction
- •8.Idiopathic diabetes (mellitus)
- •9.Juvenile onset diabetes (mellitus)
排除标准
- •1. Patient age less than two year and more than 16 year
- •2. Patients of type 2 diabetes.
- •3. Any systematic and severe illness requiring hospitalization.
- •4. History of hypersensitivity to any drug.
- •5. Patients whose parents are not willing to give consent for clinical trial.
- •6. Active case of DKA and blood glucose level more than 600 mg/dl.
- •7. Ketosis-prone diabetes (mellitus), gestational diabetes.
- •8. Hyperglycemia NOS
- •9. Neonatal diabetes mellitus
- •10. Post pancreatectomy diabetes mellitus.
- •11. Post procedural diabetes mellitus.
- •12. Secondarydiabetes mellitus NEC.
研究者
相似试验
未知
不适用
A RANDOMIZED, OPEN LABEL, ACTIVE-CONTROLLED STUDY OF THE SAFETY, EFFICACY, AND PHARMACOKINETICS OF FERUMOXYTOL COMPARED WITH ORAL IRON FOR THE TREATMENT OF IRON DEFICIENCY ANEMIA IN PEDIATRIC SUBJECTS WITH NONDIALYSIS-DEPENDENT CHRONIC KIDNEY DISEASEPER-019-11AMAG Pharmaceuticals, Inc.,3
未知
不适用
A RANDOMIZED, OPEN LABEL, ACTIVE-CONTROLLED STUDY OF THE SAFETY, EFFICACY, AND PHARMACOKINETICS OF FERUMOXYTOL COMPARED WITH ORAL IRON FOR THE TREATMENT OF IRON DEFICIENCY ANEMIA IN PEDIATRIC SUBJECTS WITH DIALYSIS-DEPENDENT CHRONIC KIDNEY DISEASEPER-023-11AMAG Pharmaceuticals, Inc.,1
尚未招募
2 期
Role of combination antifungal therapy (Liposomal Amphotericin B and Posaconazole) in MucormycosisCTRI/2021/07/034907AIIMS Department of Medicine
已完成
4 期
Clinical trial on Immunity and antiviral for quarantine patients of COVID-19CTRI/2020/06/025527Vopec Pharmaceuticals Pvt Ltd
已完成
3 期
Clinical trial on COVID 19 patients to Improve ImmunityCTRI/2020/08/027041Venkat Pharma